MTOR and hepatocellular carcinoma: Several common dysregulated pathways for HCC such as VEGF (32), MAPK (28), AKT/mTOR (33), β-catenin/Wnt (34), JAK/STAT (34), and Notch (35) were also activated in viable HCC regardless of treatment history.